David T. Howton Sells 7,000 Shares of Sarepta Therapeutics Inc. (SRPT) Stock
Sarepta Therapeutics Inc. (NASDAQ:SRPT) SVP David T. Howton sold 7,000 shares of the business’s stock in a transaction dated Thursday, September 22nd. The stock was sold at an average price of $60.00, for a total transaction of $420,000.00. Following the sale, the senior vice president now directly owns 28,453 shares of the company’s stock, valued at approximately $1,707,180. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) opened at 62.24 on Thursday. The firm’s market capitalization is $2.98 billion. Sarepta Therapeutics Inc. has a 12-month low of $8.00 and a 12-month high of $63.73. The firm’s 50-day moving average is $33.80 and its 200-day moving average is $23.24.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by $0.16. During the same quarter in the previous year, the firm posted ($0.87) EPS. Equities research analysts forecast that Sarepta Therapeutics Inc. will post ($4.17) EPS for the current fiscal year.
A number of institutional investors have recently bought and sold shares of SRPT. BlackRock Fund Advisors increased its position in Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock valued at $32,439,000 after buying an additional 36,371 shares during the period. State Street Corp increased its position in Sarepta Therapeutics by 54.0% in the first quarter. State Street Corp now owns 2,467,376 shares of the company’s stock valued at $48,168,000 after buying an additional 865,658 shares during the period. Commonwealth Equity Services Inc acquired a new position in Sarepta Therapeutics during the second quarter valued at $302,000. National Planning Corp increased its position in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock valued at $242,000 after buying an additional 275 shares during the period. Finally, TIAA CREF Investment Management LLC increased its position in Sarepta Therapeutics by 5.5% in the first quarter. TIAA CREF Investment Management LLC now owns 216,707 shares of the company’s stock valued at $4,230,000 after buying an additional 11,334 shares during the period. Hedge funds and other institutional investors own 72.09% of the company’s stock.
A number of analysts have recently commented on SRPT shares. Royal Bank Of Canada reissued a “hold” rating and set a $5.00 target price on shares of Sarepta Therapeutics in a research note on Friday, June 3rd. Vetr raised shares of Sarepta Therapeutics from a “strong sell” rating to a “buy” rating and set a $17.28 price objective for the company in a research note on Thursday, June 2nd. RBC Capital Markets raised shares of Sarepta Therapeutics from a “sector perform” rating to an “outperform” rating in a research note on Monday, September 19th. William Blair reaffirmed a “market perform” rating on shares of Sarepta Therapeutics in a research note on Monday, June 27th. Finally, Needham & Company LLC upped their price objective on shares of Sarepta Therapeutics from $20.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, July 22nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $50.28.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.